-
公开(公告)号：EP2571352A1
公开(公告)日：2013-03-27
申请号：EP11784333.4
申请日：2011-05-20
IPC分类号： A01N37/18
CPC分类号： C07C235/74 , C07C233/54 , C07C237/22 , C07C259/06 , C07C2601/08 , C07C2602/26 , C07D215/08 , C07D215/40 , C07D333/38 , C07D401/12 , C07D403/12 , C07D405/12
摘要： This disclosure is related to compounds having the structure wherein Ar1, Ar2, R1-R6, Z, m, n, o, and p are defined herein. This disclosure also relates to pharmaceutical compositions comprising the above compounds and methods for their use.
-
公开(公告)号：EP4422503A1
公开(公告)日：2024-09-04
申请号：EP22888141.3
申请日：2022-10-26
申请人： Memorial Sloan Kettering Cancer Center , Memorial Hospital for Cancer and Allied Diseases , Sloan-Kettering Institute for Cancer Research
CPC分类号： A61B6/5205 , A61B6/037 , G06T11/008
-
公开(公告)号：EP2986644B1
公开(公告)日：2022-07-27
申请号：EP14785790.8
申请日：2014-04-15
-
公开(公告)号：EP3533792B1
公开(公告)日：2021-05-05
申请号：EP19169275.5
申请日：2013-06-04
IPC分类号： C07D401/04 , A61K31/4439 , A61K31/4184 , A61P35/00
-
公开(公告)号：EP2817619B1
公开(公告)日：2018-07-25
申请号：EP13752111.8
申请日：2013-02-22
IPC分类号： A61K39/395 , A61P35/00 , G01N33/50 , G01N33/574 , C07K16/28
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2818 , G01N33/5011 , G01N2333/70503 , G01N2800/52
摘要： Efficacy of a therapeutic to enhance antitumor immunity in a patient is predicted, where the therapeutic is one that targets an immunomodulatory leukocyte membrane protein (ILMP) to enhance immune activity. Peripheral blood sample from the patient is tested for levels of monocytes having specific cell surface markers (CD14+, HLA-DRlow) prior to treatment. Low levels of monocytes of this type (PBM14+HLA-DRlow) indicate a greater likelihood of therapeutic efficacy. In specific exemplary embodiments of the invention, the therapeutic is an antibody to CTLA4, such as ipilimumab or tremelimumab.
-
公开(公告)号：EP3338770A1
公开(公告)日：2018-06-27
申请号：EP17198166.5
申请日：2011-03-08
IPC分类号： A61K31/122 , A61P35/00
CPC分类号： A61K31/365 , A61K9/0019 , A61K31/122 , A61K31/352 , A61N5/10 , C07D493/08 , C07D493/18 , C09B13/02 , C09B61/00 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit antiproliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B):
or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.-
公开(公告)号：EP2280987B1
公开(公告)日：2018-05-23
申请号：EP09731210.2
申请日：2009-04-08
发明人： GIN, David , ADAMS, Michelle , DENG, Kai , PERL, Nicholas , WON, Annie , LIVINGSTON, Philip , RAGUPATHI, Govind
IPC分类号： C07H15/24 , A61K31/704 , A61P37/04
CPC分类号： C07H15/256 , A61K31/7024 , A61K31/704 , A61K39/385 , C07H13/08 , C07H15/24
摘要： The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
-
公开(公告)号：EP2986120B1
公开(公告)日：2017-12-13
申请号：EP14784651.3
申请日：2014-04-15
发明人： LUO, Minkui , ZHENG, Weihong
摘要： Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure and are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.
-
公开(公告)号：EP3140274A1
公开(公告)日：2017-03-15
申请号：EP15788940.3
申请日：2015-05-08
CPC分类号： C07C50/12 , C07C50/14 , C07C233/32 , C07C323/22 , C07C323/30 , C07C2601/14 , C07C2602/10 , C07D215/38 , C07D217/02 , C07D243/08 , C07D295/116 , C09B13/02
摘要： Provided herein are compounds of (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions and methods involving the inventive compounds for the treatment of proliferative diseases (e.g., cancer (e.g., leukemia, breast cancer, melanoma, metastatic cancer) and diseases associated with inappropriate SET8 activity. Also provided are methods for inhibiting SET8 and methods for labelling SET8.
摘要翻译： 本文提供了（I）化合物及其药学上可接受的盐，溶剂化物，水合物，多晶型物，共晶体，互变异构体，立体异构体和前药。 还提供了涉及用于治疗增殖性疾病（例如癌症（例如，白血病，乳腺癌，黑素瘤，转移性癌症）和与不适当的SET8活性相关的疾病的本发明化合物的药物组合物和方法。还提供了抑制SET8和 SET8标签的方法。
-
公开(公告)号：EP2729806B1
公开(公告)日：2017-02-22
申请号：EP12811358.6
申请日：2012-07-06
发明人： CHIOSIS, Gabriela , TALDONE, Tony , ALPAUGH, Mary, L. , GOMES-DAGAMA, Erica, M. , GUZMAN, Monica, L. , ZONG, Hongliang
IPC分类号： G01N33/574 , A61K51/04 , A61K31/52 , G01N33/50
CPC分类号： A61K51/0459 , A61K31/52 , G01N33/5011 , G01N33/5017 , G01N33/5044 , G01N33/574 , G01N33/57407 , G01N33/57426 , G01N2500/04 , G01N2800/52
-
-
-
-
-
-
-
-
-
搜索结果
439 条记录 (耗时 0.073 秒)
